Ken Griffin Rockwell Medical, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$1.45 - $1.92 $2,610 - $3,456	1,800 Added 19.57%	11,000 $19,000
Q1 2024 May 15, 2024	SELL	$1.23 - $1.86 $492 - $744	-400 Reduced 4.17%	9,200 $15,000
Q4 2023 Feb 14, 2024	BUY	$1.58 - $2.44 $2,370 - $3,660	1,500 Added 18.52%	9,600 $18,000
Q3 2023 Nov 14, 2023	SELL	$1.83 - $6.19 $17,568 - $59,424	-9,600 Reduced 54.24%	8,100 $16,000
Q2 2023 Aug 14, 2023	BUY	$1.8 - $5.46 $28,800 - $87,360	16,000 Added 941.18%	17,700 $96,000
Q1 2023 May 15, 2023	BUY	$1.03 - $2.62 $206 - $524	200 Added 13.33%	1,700 $3,000
Q4 2022 Feb 14, 2023	BUY	$0.84 - $1.32 $1,260 - $1,980	1,500 New	1,500 $1,000

6.28M

11K

32.1K

Ticker RMTI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 10,675,200
Market Cap $32.5M
Description
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iro...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.